Our results demonstrate that allergic rhinitis can slow down the growth and development of the whole body, and the use of CCR3 monoclonal antibodies can improve this condition of delayed growth and development, and the therapeutic antibody concentration is sufficient to have a significant therapeutic effect when it is effective. This evidence concerns the gene CCR3 and allergic rhinitis.